Lithuania
Genome, founded in 2018, is positioning itself as a pioneering force in the EU fintech landscape. Headquartered in Lithuania, the company offers a suite of comprehensive financial services aimed at companies spanning multiple industries. Their platform stands out for its ability to facilitate seamless SEPA Instant, credit, and international transactions, catering to the growing need for multi-currency operations.
The firm effectively blends diverse financial tasks into an intuitive digital interface, enabling businesses to manage global finances and operations effortlessly once they acquire an IBAN. Unique offerings such as virtual and physical Visa Business cards are fortified with advanced payment safety tools, gaining the trust of users concerned about security.
Despite its strong market proposition, Genome has yet to announce its last investment or related investors. The company presents a potentially lucrative opportunity for venture capitalists looking to invest in the burgeoning fields of financial services and payments.
